EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Viatris's Enterprise Value is $30,381 Mil.
Viatris's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $776 Mil. Therefore, Viatris's EV-to-EBIT for today is 39.15.
The historical rank and industry rank for Viatris's EV-to-EBIT or its related term are showing as below:
VTRS'
s EV-to-EBIT Range Over the Past 10 Years
Min: -1447.87 Med: 25.12 Max: 70.34
Current: 39.15
During the past 13 years, the highest EV-to-EBIT of Viatris was 70.34. The lowest was -1447.87. And the median was 25.12.
VTRS's EV-to-EBIT is ranked worse than 83.08% of 668
companies
in the Drug Manufacturers industry
Industry Median: 16.995
vs VTRS: 39.15
The historical data trend for Viatris's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris EV-to-EBIT Distribution
For the Drug Manufacturers industry and Healthcare sector, Viatris's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Viatris's EV-to-EBIT falls into.
Viatris's current Enterprise Value is $30,381 Mil.
Viatris's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $776 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (NAS:VTRS) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Viatris's Enterprise Value for the quarter that ended in Dec. 2023 was $30,191 Mil.
Viatris's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $776 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Viatris's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTRS has been successfully added to your 